Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Open access
Kelley, Robin Kate, Ueno, Makoto, Yoo, Changhoon, Finn, Richard S, Furuse, Junji, Ren, Zhenggang, Yau, Thomas, Klümpen, Heinz-Josef, Chan, Stephen L, Ozaka, Masato, Verslype, Chris, Bouattour, Mohamed, Park, Joon Oh, Barajas, Olga, Pelzer, Uwe, Valle, Juan W, Yu, Li, Malhotra, Usha, Siegel, Abby B, Edeline, Julien, Vogel, Arndt, Akce, Mehmet, Ales Diaz, Inmaculada, Alves, Gustavo, Anand, Sumitra, Arslan, Cagatay, Asselah, Jamil, Assenat, Eric, Aubin, Francine, Bai, Li-Yuan, Bai, Yuxian, Barajas, Olga, Bates, Susan, Begbie, Stephen, Ben-Aharon, Irit, Beri, Nina, Berres, Marie-Luise, Blanc, Jean-Frederic, Borbath, Ivan, Bordonaro, Robert, Bouattour, Mohamed, Brandi, Giovanni, Burgoyne, Adam, Butthongkomvong, Kritiya, Camandaroba, Marcos, Cao, Ke, Carballido, Marcela, Chan, Stephan Lam, Chen, Jen-Shi, Chen, Ming-Huang, Chen, Xiaoming, Cheng, Ashley, Chiu, Tai-Jan, Choi, Hye Jin, Chon, Hong Jae, Collignon, Joelle, Cubillo Gracian, Antonio, Davis, Sarah, de Carvalho, Ricardo Saraiva, de Groot, D.J.A., Demols, Anne, De Vos, Judith, Diab, Maria, Easaw, Jacob, Eatock, Martin, Edeline, Julien, Elias, Rawad, Eskens, Fredericus, Falcone, Alfredo, Fernandez, Plinio, Finn, Richard, Franke, Fabio, Furukawa, Masayuki, Furuse, Junji, Gbolahan, Olumide, Geboes, Karen, Geneser, Keri-Lee, Geng, Zhimin, Geva, Ravit, Gillmore, Roopinder, Goetze, Thorsten, Gou, Hongfeng, Grasselli, Julieta, Gu, Shanzhi, Gumus, Mahmut, Haj Mohammad, Nadia, Hao, Chunyi, Harputluoglu, Hakan, Hatoum, Hassan, Heinemann, Volker, Ho, Wang Kwong, Hsu, Chiun, Hubert, Ayala, Hwang, Juneul, Inanc, Mevlude, Iseas, Soledad, Jeyasingam, Vaishnavi, Jimenez Fonseca, Paula, Joubert, Warren, Juengsamarn, Jitlada, Kaen, Diego, Kanai, Masashi, Kasper-Virchow, Stefan, Kazemi, Ghazaleh, Kelleher, Fergal, Kelley, Robin, Kim, Jin Won, Kim, Jong Gwang, Kinupe Abrahao, Ana Beatriz, Klumpen, Heinz, Kochenderfer, Mark, Kose, Fatih, Lam, Ho Ching, Lee, Choong-kun, Lee, Hyun Woo, Lee, Margaret, Lee, Myung Ah, Lee, Wai Man Sarah, Le Sourd, Samuel, Li, Dongliang, Li, Wei, Liang, Houjie, Liang, Tingbo, Lim, Chun Sen, Lingerfelt, Brian, Lopez, Charles, Low, John, Macarulla Mercade, Teresa, Malka, David, Mao, Yimin, Masi, Gianluca, McCune, Steven, McDermott, Ray, McWhirter, Elaine, Mendez, Guillermo, Milella, Michele, Mizuno, Nobumasa, Mizutani, Tomonori, Moniz, Camila, Morales, Luisa, Munoz Martin, Andres Jesús, Nervi, Bruno, Ngamphaiboon, Nuttapong, Oh, Sang Cheul, Oksuzoglu, Berna, Outlaw, Darryl, Ozaka, Masato, Ozguroglu, Mustafa, Ozyilkan, Ozgur, Painemal, Claudio, Pan, Yueyin, Park, Joon Oh, Pelzer, Uwe, Peng, Chuang, Petorin, Caroline, Pezet, Denis, Power, Derek, Qin, Shukui, Ren, Zhenggang, Roohullah, Aflah, Ryu, Hyewon, Salman, Pamela, Sasaki, Mitsuhito, Sasidharan, Rita, Satoh, Taroh, Schulze, Kornelius, Scott-Brown, Martin, Segovia, Ruben, Seufferlein, Thomas, Siena, Salvatore, Sinapi, Isabelle, Smolenschi, Cristina, Song, Tianqiang, Sookprasert, Aumkhae, Soparattanapaisarn, Nopadol, Starling, Naureen, Stein, Stacey, Stemmer, Salomon, Su, Haichuan, Sugimoto, Rie, Suksombooncharoen, Thatthan, Tam, Vincent, Tan, Ai Lian, Tan, Chih Kiang, Tanasanvimon, Suebpong, Tonini, Giuseppe, Tortora, Giampaolo, Tsuji, Akihito, Ueno, Makoto, Uribe, Rodrigo, Venerito, Marino, Verdaguer Mata, Helena, Verslype, Chris, Victorino, Ana Paula, Vogel, Arndt, Wade, James, Waldschmidt, Dirk Thomas, Wang, Lu, Wan Isahk, Wan Zamaniah, Wasan, Harpeet, Weschenfelder, Rui, Wong, Chun Yin, Wong, Yoke Fui, Yalcin, Suayib, Yanez Weber, Patricio, Yang, Xuezhong, Yasui, Hisateru, Yau, Thomas, Yazici, Ozan, Yen, Chia-Jui, Ying, Jieer, Yoo, Changhoon, Yu, Wenchang, Zhao, Haitao · 2023 · The Lancet

Abstract

Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.Methods KEYNOTE-966 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 175 medical centres globally. Eligible participants were aged 18 years or older; had previously untreated, unresectable, locally advanced or metastatic biliary tract cancer; had disease measurable per Response Evaluation Criteria in Solid Tumours version 1.1; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible participants were randomly assigned (1:1) to pembrolizumab 200 mg or placebo, both administered intravenously every 3 weeks (maximum 35 cycles), in combination with gemcitabine (1000 mg/m 2 intravenously on days 1 and 8 every 3 weeks; no maximum duration) and cisplatin (25 mg/m 2 intravenously on days 1 and 8 every 3 weeks; maximum 8 cycles). Randomisation was done using a central interactive voice-response system and stratified by geographical region, disease stage, and site of origin in block sizes of four. The primary endpoint of overall survival was evaluated in the intention-to-treat population. The secondary endpoint of safety was evaluated in the as-treated population. This study is registered at ClinicalTrials.gov, NCT04003636.Findings Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]). In the as-treated population, the maximum adverse event grade was 3 to 4 in 420 (79%) of 529 participants in the pembrolizumab group and 400 (75%) of 534 in the placebo group; 369 (70%) participants in the pembrolizumab group and 367 (69%) in the placebo group had treatment-related adverse events with a maximum grade of 3 to 4. 31 (6%) participants in the pembrolizumab group and 49 (9%) in the placebo group died due to adverse events, including eight (2%) in the pembrolizumab group and three (1%) in the placebo group who died due to treatment-related adverse events.Interpretation Based on a statistically significant, clinically meaningful improvement in overall survival compared with gemcitabine and cisplatin without any new safety signals, pembrolizumab plus gemcitabine and cisplatin could be a new treatment option for patients with previously untreated metastatic or unresectable biliary tract cancer.Funding Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(23)00727-4

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 1,169

Metadata

Authors
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., Verslype, C., Bouattour, M., Park, J. O., Barajas, O., Pelzer, U., Valle, J. W., Yu, L., Malhotra, U., Siegel, A. B., Edeline, J., Vogel, A., Akce, M., Ales Diaz, I., Alves, G., Anand, S., Arslan, C., Asselah, J., Assenat, E., Aubin, F., Bai, L.-Y., Bai, Y., Barajas, O., Bates, S., Begbie, S., Ben-Aharon, I., Beri, N., Berres, M.-L., Blanc, J.-F., Borbath, I., Bordonaro, R., Bouattour, M., Brandi, G., Burgoyne, A., Butthongkomvong, K., Camandaroba, M., Cao, K., Carballido, M., Chan, S. L., Chen, J.-S., Chen, M.-H., Chen, X., Cheng, A., Chiu, T.-J., Choi, H. J., Chon, H. J., Collignon, J., Cubillo Gracian, A., Davis, S., de Carvalho, R. S., de Groot, D. J. A., Demols, A., De Vos, J., Diab, M., Easaw, J., Eatock, M., Edeline, J., Elias, R., Eskens, F., Falcone, A., Fernandez, P., Finn, R., Franke, F., Furukawa, M., Furuse, J., Gbolahan, O., Geboes, K., Geneser, K.-L., Geng, Z., Geva, R., Gillmore, R., Goetze, T., Gou, H., Grasselli, J., Gu, S., Gumus, M., Haj Mohammad, N., Hao, C., Harputluoglu, H., Hatoum, H., Heinemann, V., Ho, W. K., Hsu, C., Hubert, A., Hwang, J., Inanc, M., Iseas, S., Jeyasingam, V., Jimenez Fonseca, P., Joubert, W., Juengsamarn, J., Kaen, D., Kanai, M., Kasper-Virchow, S., Kazemi, G., Kelleher, F., Kelley, R., Kim, J. W., Kim, J. G., Kinupe Abrahao, A. B., Klumpen, H., Kochenderfer, M., Kose, F., Lam, H. C., Lee, C.-K., Lee, H. W., Lee, M., Lee, M. A., Lee, W. M. S., Le Sourd, S., Li, D., Li, W., Liang, H., Liang, T., Lim, C. S., Lingerfelt, B., Lopez, C., Low, J., Macarulla Mercade, T., Malka, D., Mao, Y., Masi, G., McCune, S., McDermott, R., McWhirter, E., Mendez, G., Milella, M., Mizuno, N., Mizutani, T., Moniz, C., Morales, L., Munoz Martin, A. J., Nervi, B., Ngamphaiboon, N., Oh, S. C., Oksuzoglu, B., Outlaw, D., Ozaka, M., Ozguroglu, M., Ozyilkan, O., Painemal, C., Pan, Y., Park, J. O., Pelzer, U., Peng, C., Petorin, C., Pezet, D., Power, D., Qin, S., Ren, Z., Roohullah, A., Ryu, H., Salman, P., Sasaki, M., Sasidharan, R., Satoh, T., Schulze, K., Scott-Brown, M., Segovia, R., Seufferlein, T., Siena, S., Sinapi, I., Smolenschi, C., Song, T., Sookprasert, A., Soparattanapaisarn, N., Starling, N., Stein, S., Stemmer, S., Su, H., Sugimoto, R., Suksombooncharoen, T., Tam, V., Tan, A. L., Tan, C. K., Tanasanvimon, S., Tonini, G., Tortora, G., Tsuji, A., Ueno, M., Uribe, R., Venerito, M., Verdaguer Mata, H., Verslype, C., Victorino, A. P., Vogel, A., Wade, J., Waldschmidt, D. T., Wang, L., Wan Isahk, W. Z., Wasan, H., Weschenfelder, R., Wong, C. Y., Wong, Y. F., Yalcin, S., Yanez Weber, P., Yang, X., Yasui, H., Yau, T., Yazici, O., Yen, C.-J., Ying, J., Yoo, C., Yu, W., & Zhao, H.
Affiliations
  • University of California, San Francisco (US)
  • University of California, Los Angeles (US)
  • Chinese University of Hong Kong (HK)
  • University of Manchester (GB)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • Inserm (FR)
  • Samsung Medical Center (KR)
  • University of Hong Kong (HK)
  • Amsterdam University Medical Centers (NL)
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-06
Volume
401
Issue
10391
Pages
1853-1865
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4365998338
Cited by
1,169
References
32
Citations by year
2026: 358 · 2025: 418 · 2024: 302 · 2023: 89
FWCI
311.55
Type
journal article
Language
en
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, other-oa)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • HAL (submittedVersion, cc-by-nc)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Merck Sharp and Dohme
Topics
  • Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
Keywords
pembrolizumab, gemcitabine, cisplatin, biliary tract cancer, immune checkpoint inhibitors, combination chemotherapy, overall survival, immune-related adverse events, anti-PD-1 therapy, metastatic cholangiocarcinoma, gallbladder cancer, cholangiocarcinoma, safety and tolerability
MeSH terms
Immune Checkpoint Inhibitors, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Cisplatin, Double-Blind Method, Humans, Tumor Microenvironment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00727-4
The paper
Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., Verslype, C., Bouattour, M., Park, J. O., Barajas, O., Pelzer, U., Valle, J. W., Yu, L., Malhotra, U., Siegel, A. B., . . . Zhao, H. (2023). Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)00727-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.